Back to search results

Imaging with Fluorine F 18 Fluorthanatrace for Solid Tumors

This study is looking at a new imaging method called Fluorine F 18 Fluorthanatrace (FTT) PET/CT for patients with solid tumors, including breast, ovarian, fallopian tube, or primary peritoneal cancer. FTT is a special tracer that helps doctors see how active a protein called PARP-1 is in tumor cells. By using FTT with PET/CT scans, researchers hope to find more tumor cells and better understand how they respond to treatment. The study will also check if FTT uptake is related to BRCA gene mutations. This study is currently enrolling women aged 18 and older who have a known or suspected solid tumor with at least one lesion 1.0 cm or larger.

Study design
This interventional study plans to enroll 300 participants. It is not specified if it is randomized or blinded.
What's involved
You would receive Fluorine F 18 Fluorthanatrace and Fludeoxyglucose F-18 intravenously (into a vein) and undergo PET/CT scans. Some participants may also have tumor tissue samples taken.
Compensation
Not stated in the trial record.
Follow-up
Your PARP-1 activity will be assessed for up to 4 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03604315

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~300 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Computed TomographyFludeoxyglucose F-18Fluorine F 18 FluorthanatracePositron Emission Tomography

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Poly (ADP-ribose) polymerase inhibitor (PARP)-1 activity as assessed by fluorine F 18 fluorthanatrace positron emission tomography/computed tomography
Measured over Up to 4 years

Conditions

Breast Carcinoma
Fallopian Tube Carcinoma
Ovarian Carcinoma
Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Solid Neoplasm

Explore related trials

Breast CarcinomaFallopian Tube CarcinomaMalignant Ovarian NeoplasmPrimary Peritoneal CancerSolid Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Lilie L Lin · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Lilie Lin
[email protected]
713-563-2300
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

History of known or suspected solid tumor.
At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography \[CT\], magnetic resonance imaging \[MRI\], ultrasound, fludeoxyglucose \[FDG\] PET/CT).

Exclusion

Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \< 2 weeks prior to screening as standard of care.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.

What this trial measures

  • Poly (ADP-ribose) polymerase inhibitor (PARP)-1 activity as assessed by fluorine F 18 fluorthanatrace positron emission tomography/computed tomographyUp to 4 years

    Data will be generated for semi-parametric uptake of both tracers by patient and by lesion as well as by PARP activity, and summarized as mean and standard deviation (SD) across patients. For patients for whom tumor tissue is saved, the correlation of uptake values and PARP activity as assayed from biopsy specimens will be measured using the rank correlation (Spearman's rho), and test for significance compared to no correlation.